Guidelines

Zhou J. · Sun H. · Wang Z. · Cong W. · Zeng M. · Zhou W. · Bie P. · Liu L. · Wen T. · Kuang M. · Han G. · Yan Z. · Wang M. · Liu R. · Lu L. · Ren Z. · Zeng Z. · Liang P. · Liang C. · Chen M. · Yan F. · Wang W. · Hou J. · Ji Y. · Yun J. · Bai X. · Cai D. · Chen W. · Chen Y. · Cheng W. · Cheng S. · Dai C. · Guo W. · Guo Y. · Hua B. · Huang X. · Jia W. · Li Q. · Li T. · Li X. · Li Y. · Li Y. · Liang J. · Ling C. · Liu T. · Liu X. · Lu S. · Lv G. · Mao Y. · Meng Z. · Peng T. · Ren W. · Shi H. · Shi G. · Shi M. · Song T. · Tao K. · Wang J. · Wang K. · Wang L. · Wang W. · Wang X. · Wang Z. · Xiang B. · Xing B. · Xu J. · Yang J. · Yang J. · Yang Y. · Yang Y. · Ye S. · Yin Z. · Zeng Y. · Zhang B. · Zhang B. · Zhang L. · Zhang S. · Zhang T. · Zhang Y. · Zhao M. · Zhao Y. · Zheng H. · Zhou L.. · Zhu J. · Zhu K. · Liu R. · Shi Y. · Xiao Y. · Zhang L. · Yang C. · Wu Z. · Dai Z. · Chen M. · Cai J. · Wang W. · Cai X. · Li Q. · Shen F. · Qin S · Teng G. · Dong J. · Fan J.
Abstract

Background: Primary liver cancer, around 75%–85% are hepatocellular carcinoma in China, is the fourth most common malignancy and the second leading cause of tumor-related death, thereby posing a significant threat to the life and health of the Chinese people. Summary: Since the publication of Guidelines for Diagnosis and Treatment of Primary Liver Cancer in China in June 2017, which were updated by the National Health Commission in December 2019, additional high-quality evidence has emerged from researchers worldwide regarding the diagnosis, staging, and treatment of liver cancer, that requires the guidelines to be updated again. The new edition (2022 Edition) was written by more than 100 experts in the field of liver cancer in China, which not only reflects the real-world situation in China, but also may re-shape the nationwide diagnosis and treatment of liver cancer. Key Messages: The new guideline aims to encourage the implementation of evidence-based practice, and improve the national average five-year survival rate for patients with liver cancer, as proposed in the "Health China 2030 Blueprint."

The Author(s). Published by S. Karger AG, Basel

Article / Publication Details Open Access License / Drug Dosage / Disclaimer This article is licensed under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC). Usage and distribution for commercial purposes requires written permission.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.